Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
Second-line therapies of patients with early progression under CDK4/6-inhibitor in first-line – data from the registry platform OPAL.

Marschner N, Harbeck N, Thill M, Stickeler E, Zaiss M, Nusch A, u. a. 2022.

Oncol Res Treat. 2022;45(suppl 2)(P345):107.

Download

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DGHO / Journal:
OPAL
2022
Klinische Plattform zur Erforschung molekularer Testung, Behandlung und Krankheitsverlauf von Patienten mit Lungenkrebs (CRISP): Real-World Evidence zu NSCLC Patienten behandelt mit Radiochemotherapie in Deutschland – AIO-TRK-0315.

Eberhardt WEE, Passlick B, Stuschke M, Groeschel A, Christopoulos P, Reck M, et al. 2022.

Oncol Res Treat 2021;44:1–335

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
CRISP
2022
Behandlung von Patienten mit fortgeschrittenem Urothelkarzinom in der Routineversorgung in Deutschland: Erste Daten aus der CARAT-UBC-Kohorte.

Goebell PJ, Müller L, Bögemann M, Rauh, Jacqueline, Nusch, Arnd, Andres-Pons, Amparo, et al. 2022.

Oncol Res Treat. 2022;45 (suppl 2)(P1015):319–20.

Download

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
CARAT
2022
The prospective, national research platform AZURITE: Current routine care of metastatic colorectal cancer in Germany.

Michl M, Kullmann F, Schnell R, Marschner P, von der Heyde E, Dörfel S, u. a. 2022.

Oncol Res Treat. 2022;45(suppl 2)(P1001):313–4.

Download

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
AZURITE
2022
Prognostic factors in non-small-cell lung cancer: insights from the German CRISP registry.

M Metzenmacher, F Griesinger, H-D Hummel, C Elender, H Schäfer, M de Wit, U Kaiser, J Kern, M Jänicke, L Spring, S Zacharias, A Kaiser-Osterhues, A Groth, A Hipper, G Zaun, S Dörfel, B Güldenzoph, L Müller, J Uhlig, M Thomas, M Sebastian, W E E Eberhardt, for the CRISP Registry Group, 2022.

European Respiratory Journal Jan 2022, 2201336; DOI: 10.1183/13993003.01336-2022

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: - / Journal: European Respiratory Journal
CRISP
2022
Was können Register leisten? Warum Real World Data zur Versorgungsrealität aus Registern so wichtig sind.

Griesinger F, Jänicke M. Prävention und Gesundheitsförderung. 2022 Aug:1-6. PMCID: PMC9395927.

Indikation: Other, Sonstige / Veranstaltung: - / Journal: Prävention und Gesundheitsförderung
Registerübergreifend
2022
Prophylaxis of chemotherapy-induced neutropenia with lipegfilgrastim in patients with lung cancer: final results from the non-interventional study NADIR.

C Geßner, T Fietz, C Losem, A Lück, H Schulz, B Niemeier, M Groschek, H Eschenburg, R Weide, A Kretzschmar, N Frost, J Hipp, J Harde, C D Matillon, S Grebhardt, K Potthoff, 2022.
Current Medical Research and Opinion, DOI: 10.1080/03007995.2022.2113693

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: - / Journal: Current Medical Research and Opinion
NADIR
2022
Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany.

F Griesinger, M Pérol, N Girard, I Durand-Zaleski, S Zacharias, L Bosquet, M Jänicke, X Quantin, A Groth, A Fleitz, A Calleja, S Patel, L Lacoin, M J Daumont, J R Penrod, R Carroll, D Waldenberger, D Reynaud, M Thomas, C Chouaid, 2022.

Lung Cancer, Volume 172, 2022, Pages 65-74. https://doi.org/10.1016/j.lungcan.2022.08.001.

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: - / Journal: Lung Cancer
CRISP
2022
Significance of Patient-Reported Outcomes for Metastatic Breast Cancer Patients.

Hillebrand L, E, Söling U, Marschner N, 2022.
Oncol Res Treat 2022;45:423-429. doi: 10.1159/000521826

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: Oncology Research and Treatment
Projektübergreifend
2022
Real-world patient-reported outcomes of breast cancer or prostate cancer patients receiving antiresorptive therapy for bone metastases: Final results of the PROBone registry study.

A Jakob, M-O Zahn, A Nusch, T Werner, R Schnell, M Frank, N Hamm, K-U Däßler, C Losem, M Welslau, P Hoevel, K Potthoff, 2022.

Journal of Bone Oncology, Volume 33, 2022. https://doi.org/10.1016/j.jbo.2022.100420

Indikation: Breast Cancer, Mammakarzinom, Prostatakarzinom, Prostate Cancer / Veranstaltung: - / Journal: Journal of Bone Oncology
PRO Bone
2022